BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells

Blood

Volumn 113, Issue 19, 2009, Pages 4627-4636

  Fu, Lingchen ^a   Lin Lee, Yen Chiu ^a   Pham, Lan V ^a   Tamayo, Archito T ^a   Yoshimura, Linda C ^a   Ford, Richard J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BARRIER TO AUTOINTEGRATION FACTOR; BCL2 RELATED PROTEIN A1; CD40 LIGAND; HISTONE H3; I KAPPA B KINASE BETA; INTERLEUKIN 8; PROTEIN BCL XL; TRANSCRIPTION FACTOR REL; HISTONE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TNFRSF13C PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING SITE; CELL GROWTH; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CYTOPLASM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; B CELL LYMPHOMA; CELL CULTURE; CELL FRACTIONATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CYTOLOGY; GENETICS; LYMPHOCYTE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PLASMID; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; GENES, REL; HISTONES; HUMANS; I-KAPPA B KINASE; LYMPHOCYTES; LYMPHOMA, B-CELL; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PHOSPHORYLATION; PLASMIDS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-REL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBCELLULAR FRACTIONS;

EID: 66549095183     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-183467     Document Type: Article

References (51)

1. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-1552. (Pubitemid 32931019)
2. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172:3268-3279. (Pubitemid 38263719)
3. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3:958-965. (Pubitemid 35154010)
4. Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002;17:515-524. (Pubitemid 35223539)
5. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192:953-964. (Pubitemid 30765689)
6. Hatada EN, Do RK, Orlofsky A, et al. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol. 2003;171:761-768. (Pubitemid 36871386)
7. Morrison MD, Reiley W, Zhang M, Sun SC. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J Biol Chem. 2005;280:10018-10024. (Pubitemid 40395852)
8. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465-475. (Pubitemid 37328738)
9. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100:2973-2979.
10. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004;104:2247-2253. (Pubitemid 39331819)
11. Rahman ZS, Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol. 2004;173:6179-6188. (Pubitemid 39487775)
12. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol. 2002;168:5993-5996.
13. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med. 2005;202:1363-1374. (Pubitemid 41668739)
14. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004;20:441-453. (Pubitemid 38482122)
15. Huang X, Di Liberto M, Cunningham AF, et al. Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A. 2004;101:17789-17794. (Pubitemid 40051965)
16. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006;107:4540-4548. (Pubitemid 43801383)
17. Lin-Lee YC, Pham LV, Tamayo AT, et al. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem. 2006;281:18878-18887.
18. Zhou HJ, Pham LV, Tamayo AT, et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood. 2007;110:2121-2127.
19. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-2224.
20. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-288. (Pubitemid 38610351)
21. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med. 2002;196:743-752.
22. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene. 2006;25:6685-6705. (Pubitemid 44657846)
23. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.
24. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature. 2003;423:659-663. (Pubitemid 36713228)
25. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKKalpha is critical for cytokine-induced gene expression. Nature. 2003;423:655-659. (Pubitemid 36713227)
26. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106:3940-3947.
27. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687-2695.
28. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999;13:382-387. (Pubitemid 29108753)
29. Edelstein LC, Lagos L, Simmons M, Tirumalai H, Gelinas C. NF-kappa B-dependent assembly of an enhanceosome-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1. Mol Cell Biol. 2003;23:2749-2761. (Pubitemid 36403075)
30. Ford RJ, Goodacre A, Ramirez I, Mehta SR, Cabanillas F. Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor. Blood. 1990;75:1311-1318. (Pubitemid 20107299)
31. Verveer PJ, Rocks O, Harpur AG, Bastiaens PIH. Imaging Protein Interactions by FRET Microscopy: FRET Measurements by Acceptor Photobleaching. Cold Spring Harb. Protoc.; 2006; doi: 10.1101/pdb.prot4598.
32. Park GY, Wang X, Hu N, Pedchenko TV, Blackwell TS, Christman JW. NIK is involved in nucleosomal regulation by enhancing histone H3 phosphorylation by IKKalpha. J Biol Chem. 2006;281:18684-18690. (Pubitemid 44035529)
33. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802-808. (Pubitemid 32842685)
34. Horn F, Vriend G, Cohen FE. Collecting and harvesting biological data: the GPCRDB and NucleaRDB database. Nucleic Acids Res. 2001;29:346-349. (Pubitemid 32054489)
35. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-362.
36. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet. 2005;37:579-583. (Pubitemid 40770410)
37. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106:1392-1399. (Pubitemid 41129606)
38. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene. 2006;25:6831-6843. (Pubitemid 44657855)
39. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19:5237-5246. (Pubitemid 29339883)
40. Heyninck K, Beyaert R. Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol Cell Biol Res Commun. 2001;4:259-265. (Pubitemid 32879079)
41. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 2003;14:193-209. (Pubitemid 36693141)
42. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
43. Orlowski RZ, Baldwin AS Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002;8:385-389.
44. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817-6830.
45. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241-246.
46. Köntgen F, Grumont RJ, Strasser A, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995;9:1965-1977.
47. Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004;23:2275-2286. (Pubitemid 38496782)
48. Sanjabi S, Williams KJ, Saccani S, et al. A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev. 2005;19:2138-2151. (Pubitemid 41330316)
49. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol. 2005;6:439-445. (Pubitemid 41716756)
50. Girouard J, Reyes-Moreno C, Darveau A, Akoum A, Mourad W. Requirement of the extracellular cysteine at position six for CD40/CD40 dimer formation and CD40-induced IL-8 expression. Mol Immunol. 2005;42:773-780. (Pubitemid 40489026)
51. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther. 2007;6:460-470.